Next Article in Journal
A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples
Previous Article in Journal
Evidence of Polymorphism on the Antitrypanosomal Naphthoquinone (4E)-2-(1H-Pyrazol-3-ylamino)- 4-(1H-pyrazol-3-ylimino)naphthalen-1(4H)-one
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2013, 81(3), 865-888; doi:10.3797/scipharm.1211-20

Rivastigmine-Loaded L-Lactide-Depsipeptide Polymeric Nanoparticles: Decisive Formulation Variable Optimization

Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University under Section 3 of UGC Act-1956, Elite Status & Centre of Excellence – Govt. of Maharashtra, TEQIP Phase II Funded, Matunga, Mumbai-400019, India
*
Author to whom correspondence should be addressed.
Received: 24 November 2012 / Accepted: 28 March 2013 / Published: 28 March 2013
Download PDF [1000 KB, uploaded 29 September 2016]

Abstract

The main aim of the investigation was to explore a novel L-lactide-depsipeptide copolymer for the development of rivastigmine-loaded polymeric nanoparticles. L-lactide-depsipeptide synthesis was based on the ring opening polymerization reaction of L-lactide with the cyclodepsipeptide, cyclo(Glc-Leu), using tin 2-ethyl hexanoate as an initiator. Rivastigmine-loaded nanoparticles were prepared by the single emulsion-solvent evaporation technique. The influence of various critical formulation variables like sonication time, amount of polymer, amount of drug, stabilizer concentration, drug-to-polymer ratio, and organic-to-aqueous phase ratio on particle size and entrapment efficiency was studied. The optimized formulation having a particle size of 142.2 ± 21.3 nm with an entrapment efficiency of 60.72 ± 3.72% was obtained. Increased rivastigmine entrapment within the polymer matrix was obtained with a relatively low organic-to-aqueous phase ratio and high drug-to-polymer ratio. A decrease in the average size of the nanoparticles was observed with a decrease in the amount of polymer added and an increase in the sonication time. Prolonged sonication time, however, decreased rivastigmine entrapment. From the different lyoprotectant tested, only trehalose was found to prevent nanoparticle aggregation upon application of the freeze-thaw cycle. Drug incorporation into the polymeric matrix was confirmed by the DSC and XRD study. The spherical nature of the nanoparticles was confirmed by the SEM study. The in vitro drug release study showed the sustained release of more than 90% of the drug up to 72 h. Thus, L-lactide-depsipeptide can be used as an efficient carrier for the nanoparticle preparation of rivastigmine.
Keywords: Rivastigmine; L-lactide-depsipeptide copolymer; Nanoparticles; Particle size; Formulation variables Rivastigmine; L-lactide-depsipeptide copolymer; Nanoparticles; Particle size; Formulation variables
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

PAGAR, K.; VAVIA, P. Rivastigmine-Loaded L-Lactide-Depsipeptide Polymeric Nanoparticles: Decisive Formulation Variable Optimization. Sci. Pharm. 2013, 81, 865-888.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top